Astrana Health’s 2027 EBITDA Guidance, G&A Synergy Claims, and Medical Trend Shifts Clash in Q2 2026 Earnings Call

Date of Call: Aug 6, 2026

Financials Results

• Revenue: $973 million, up 49% year-over-year
• EPS: $0.80 per diluted share, up 45% year-over-year

Guidance:

• Raised full-year 2026 adjusted EBITDA guidance to $255 to $280 million.
• Reaffirmed full-year revenue guidance of $3.8 to $4.1 billion.
• Reaffirmed full-year free cash flow guidance of $105 to $132.5 million.
• Expect Q3 2026 revenue between $1.00 and $1.03 billion and adjusted EBITDA between $72.5 and $77.5 million.
• Expect G&A to be approximately 6% of revenue for the full year.

Business Commentary:

Revenue and Earnings Growth:

• Astrana Health reported revenue of $973 million for Q2 2026, up 49% year-over-year.
• Adjusted EBITDA reached $69 million, up 43% year-over-year, with adjusted diluted earnings per share hitting a record high of $0.80, up 45% year-over-year.
• Growth was driven by strong demand from payer and provider partners, maturation of value-based care cohorts, and the scalability of their AI-native healthcare operating system.

Medical Cost Trend Management:

• Overall medical cost trend for the year-to-date was slightly better than the full-year assumption of approximately 5.2%.
• Medicare Advantage and Original Medicare performed favorably, while commercial costs ran slightly above expectations.
• The company attributes this to disciplined medical cost trend management through better care and operational efficiencies enabled by their delegated model.

Deleveraging and Cash Flow:

• Net leverage declined to 2.26 times on a trailing 12-month basis.
• Free cash flow totaled $93 million in the first half of the year, representing approximately 69% conversion of adjusted EBITDA into free cash flow.
• This was achieved through strong cash generation and strategic deleveraging efforts.

Strategic Expansion and Integration:

• The company signed new Medicare Advantage agreements in Hawaii and Texas, and expanded relationships in California.
• Gross provider retention remained above 99% following the Prospect acquisition, with operating expense synergies at the high end of the target range.
• These efforts reflect the company's strategy to expand responsibly and enhance operating leverage.

Operating Leverage and AI Automation:

• G&A as a percentage of revenue improved by approximately 210 basis points year-over-year in Q2.
• AI agents reduced handling time in claims operations and referral management by more than 50%, creating operational capacity equivalent to approximately 60 full-time employees over the past 12 months.
• This demonstrates the impact of AI-native automation in improving productivity and reducing costs.

Sentiment Analysis:

Overall Tone: Positive

• Management highlighted 'accelerating demand', 'record profitability', 'strong free cash flow generation', 'continued momentum', and 'confidence in our updated outlook'. They also noted that outperformance 'has enabled us to continue deleveraging ahead of schedule' and that the business 'continues to generate substantial cash'.

Q&A:

• Question from Matthew Mardula (William Blair): With you talking about outperforming the full year trend assumption of about 5%, what cost trend are you currently at? And then with commercial above trend, what is impacting that segment and is it the exchange segment? And then lastly, did any segment cost trends needed to be revised versus your expectations?
  Response: Overall medical cost trend is tracking slightly better than the 5.2% assumption. Medicare Advantage and Original Medicare are slightly favorable, Medicaid is in line, and commercial is slightly above but manageable; no change to guidance is anticipated.

• Question from Matthew Mardula (William Blair): With the new members added in Texas, Hawaii, as well as in California for Medicare Advantage, and with you talking about continuing to expand membership, as we think about expansion, is MA... area that looks most favorable to you? And as we think about into the second half and into 2027, should we be expecting MA memberships to continue to grow?
  Response: The model is pair-agnostic, but due to changes in Medicaid, a higher percentage of future revenue will come from Medicare (Advantage and Original). Confidence in continued Medicare Advantage success into 2027 is expressed.

• Question from Jack Fleven (Jefferies): I wanted to just touch on MA a little and really two things... maybe what you're hearing or seeing from from payers given we are past bid deadlines... And then secondly, as you look at trend and opportunities to moderate there, any pockets you can call out or areas you might see that could be potential drivers of upside in MA as we progress through the year and into the out years.
  Response: Payer bids are not public yet, but confidence in MA success continues. Medical cost trend is already outperforming expectations, with opportunities for further improvement, such as more accurate coding to capture risk scores.

• Question from Jack Fleven (Jefferies): The G&A commentary continues to be, I think, pretty optimistic... If I try to balance those two things, can you just speak a little bit to sort of, you tracking nicely together? Is there room to go on prospect within some of the core initiatives you're putting out across the business that are separate from the synergies?
  Response: G&A as a percentage of revenue is improving due to both Prospect synergy capture (at the high end of the $12-15M target) and core operational changes, with continued declines expected.

• Question from Michael Ha (Baird): On the rebalancing of Medi-Cal lives from professional floor risks, I was wondering if you could elaborate more on this... How should we think about the expected earnings impact?
  Response: The rebalancing is driven by a desire for better financial alignment in a time of compressing margins. Transitions to full-risk arrangements are expected to occur over the next 12 months for tens of thousands of members, with the economics still being sized.

• Question from Michael Ha (Baird): On risk score capture... how should we think about the go forward annual RAF improvement? Would it be fair to presume... heading out, it might even be greater RAF improvement.
  Response: RAF improvements in existing cohorts are expected to continue historically. Growth depends on the RAF of new cohorts, with potential medium-term upside from more accurate coding in the Medicare population.

• Question from Jill Andrea Singh (Truist): First, I want to ask about second half EBITDA guidance and the implied Q4 outlook. It implies a pretty wide Q4 range of 47 to 67 million... Is there anything meaningfully different in Q4 versus Q3 this year versus prior years?
  Response: The wide Q4 range is an artifact of the annual guidance range. The quarterly cadence is similar to past years, with Q3 being the best quarter and a sequential step down into Q4.

• Question from Jill Andrea Singh (Truist): We didn't hear any thoughts on 2027. You have talked about mid to high themes year over year organic EBITDA growth in 2027. First, I want to confirm any changes to that thought process. And related to that, what requirement headwind next year?
  Response: The mid-to-high teens EBITDA growth outlook for 2027 is reaffirmed. Medicaid changes are anticipated, but portfolio rebalancing provides the right levers to continue growth in that range.

• Question from Jill Andrea Singh (Truist): Some of the large health insurers have talked about exiting Medicaid markets... Generally, how much lead time do you get to contract with plants, winning those lives?
  Response: Lead time is typically around a few months. The pair-agnostic model helps, as members can switch to another plan the company contracts with, minimizing disruption.

• Question from Janie Shen (BTIG): I just wanted to ask about some of the member attrition that you referred to earlier. Just any thoughts on what you're seeing, what you saw this quarter versus last quarter?
  Response: Attrition is largely in line with expectations: California Medicaid is at the high end of the guidance range, exchange is slightly better than assumed, and Medicare is stable.

• Question from Andrew Mock (Barclays): If you're reinvesting, say, seven plus million from the first half and still raising the guide by two and a half million, is it fair that the first half outperformed plan by 10 million or so? And is there anything driving that outperformance that's one time in nature?
  Response: Yes, the outperformance was approximately $10M, with about three-quarters reinvested. There were no material one-time items; the reinvestment is in growth opportunities for future earnings expansion.

• Question from Andrew Mock (Barclays): Why exactly is Q3 the best quarter of the year from an EBITDA perspective? And does IRA have meaningful – is that going to have a meaningful impact to seasonality this year?
  Response: Q3 is typically the best due to timing of accruals for programs like MSSP and sweeps. IRA is not a major impact; the primary drivers are ACO program profitability and sweeps.

• Question from Ryan (William Blair): Can you elaborate what's driving that [$15 million revenue reduction]... Did that hit all in the second quarter and maybe how that flows through to EBITDA?
  Response: The $15M reduction is due to CMS adjustments for fraud, waste, and abuse in the ACO REACH 2025 performance year, affecting both revenue and expense; the net impact on EBITDA was immaterial.

• Question from Jack Fleven (Jefferies): On the theme of automation, the slide presentation referenced a statistic about Astrona driving over 500,000 automated member encounters per month. And I was kind of curious what the nature of those interactions were and what the benefit is to the company from those interactions.
  Response: The automated encounters include voice, scheduling, text, medication reconciliation, etc. The benefit is enabling more frequent, lower-cost care engagement without sacrificing quality, improving outcomes and potentially reducing medical cost trend over time.

• Question from Jack Fleven (Jefferies): On the trend discussion, I wanted to see if there was anything to call out in terms of the categories of costs that are trending better within the MA and Medicare book and the categories of costs that are maybe running a little bit higher for commercial.
  Response: Medicare trend is strong and broad-based, with stable inpatient admits per 1,000. Commercial trend is slightly above expectations but concentrated in outpatient specialties and is manageable.

• Question from Matt Shea (Needham & Company): How does Hawaii fit the delegated model? What makes this market attractive? And then in Texas, maybe help us understand why the Texas ad coming in is professional risk rather than the fully delegated risk.
  Response: Hawaii is attractive for quickly building a scaled provider entity. In Texas, the new 3,000 lives are in a professional risk arrangement, but the company aims to move them to a full-risk construct as performance matures.

• Question from Matt Shea (Needham & Company): On the tech stack... is any of that going into incremental tech or AI innovation? And then if we take a step back, are you seeing your tech leadership relative to peers compound at this stage?
  Response: The current reinvestment is primarily in provider and payer growth. AI innovation is prudent and already contemplated in existing guidance. The company is focused on building its proprietary orchestration stack in-house and continues to add engineering talent.

Contradiction Point 1

2027 EBITDA Growth Outlook and Impact of Current Investments

Contradiction on whether 2027 growth includes benefits from new investments.

Jill Andrea Singh (Truist) - Jill Andrea Singh (Truist)

2026Q2: Reaffirmed mid-to-high-teens EBITDA growth outlook for medium term, including 2027... Current investments... fund new contracts/geographies; losses may be factored into 2027 guide... - Brandon Sim(CEO)

Has the mid-to-high-teens EBITDA growth outlook for 2027 changed considering Medicaid headwinds and current investments driving incremental growth? - Jack Slevin (Jefferies)

2026Q2: ...mid-to-high teens EBITDA growth outlook for 2027 and beyond remains unchanged. Investments being made this year... may not flip to profitability in 2027... - Brandon Sim(CEO)

Contradiction Point 2

Drivers of G&A Expense Improvement

Contradiction on the primary source of G&A savings between quarters.

Jack Fleven (Jefferies) - Jack Fleven (Jefferies)

2026Q2: G&A as a percentage of revenue improved over 2% year-over-year... Improvements come from both capturing prospect synergies... and core operational changes across the legacy Astrana business. - Brandon Sim(CEO)

How much of the G&A improvements come from Prospect synergies versus core efficiency/AI initiatives? - Jack Slevin (Jefferies)

2026Q2: G&A as a percentage of revenue improved by over 2% year-over-year in Q2... Improvements come from both capturing operating expense synergies... from the Prospect integration and core operational changes in the legacy Astrana business. - Brandon Sim(CEO)

Contradiction Point 3

Medical Cost Trend Performance

Contradiction on whether trend is performing above or at expectations.

Matthew Mardula (William Blair) - Matthew Mardula (William Blair)

2026Q2: Overall medical cost trend is slightly better than the guided 5.2% assumption. - Brandon Sim(CEO)

What are the current cost trends, factors impacting the commercial segment, and whether any segment cost trends needed revision given outperformance and commercial segments above trend? - Jack Slevin (Jefferies)

2026Q1: Medical cost trend performing at or above expectations (slightly better than the 5.2% plan). - Brandon Sim(CEO)

Contradiction Point 4

Medical Cost Trend Guidance

Guidance for medical cost trend shifts from being "slightly higher" than a prior range to being "slightly better than guided."

What was Matthew Mardula's question for the company during the earnings call? - Matthew Mardula (William Blair)

2026Q2: Overall medical cost trend is slightly better than the guided 5.2% assumption. - Brandon Sim(CEO)

"Given outperformance and commercial segments above trend, what are the current cost trends, what is impacting the commercial segment, and were any segment cost trends revised?" - Matthew Mardula (William Blair)

2025Q4: The company is embedding a conservative assumption of just over a 5% medical cost trend, slightly higher than the mid-4% range achieved in 2025. - Brandon Sim(CEO)

Contradiction Point 5

G&A Efficiency Target

The expected reduction in G&A as a percentage of revenue contradicts the prior year's reported performance.

Okay, let's see. The user wants me to take the input "Jack Fleven (Jefferies)" and turn it into a concise earnings-call question. The rules are strict: only one line, end with a question mark if possible, no explanations, and if it can't be a question, leave it as is.First, I need to figure out what the input represents. It looks like a person's name followed by a company or firm name in parentheses. That's typical for analysts covering a company. For example, in earnings calls, there are analysts from different firms who ask questions. So "Jack Fleven (Jefferies)" might be an analyst from Jefferies asking a question during an earnings call.Now, the task is to rephrase this into a single question. Since the input isn't a question itself, I need to infer what the question might be. Common earnings call questions from analysts could be about financial performance, future projections, challenges, etc. But without more context, it's hard to know the exact topic.But the user's instruction says if the input is too vague or lacks info, output as-is. However, maybe there's a way to form a question here. Since it's an analyst's name and firm, perhaps the question is about the company's performance or specific metrics. For example, "What were the key factors driving the company's recent financial performance?" or "Can you provide more details on the guidance for next quarter?"But the problem is, without knowing the specific company or the context of the earnings call, the question could be too generic. However, the user might expect a generic question based on the analyst's identity. Alternatively, maybe the input is part of a transcript where the analyst is asking a question, and the user wants to extract that into a question format. Wait, the input is just the name and firm. If this is part of an earnings call transcript, typically after the name and firm, the analyst would ask a question. Since the input is only the name and firm, maybe the actual question isn't provided. In that case, the input isn't a question and lacks enough info to form a clear one. But the user says to output the input as-is if it's not a question or too vague. However, maybe there's a standard way to phrase it. For example, "What are your thoughts on the recent market trends, Jack Fleven (Jefferies)?" But the user's rules say to output only the final question text, exactly one line. Alternatively, maybe the input is a speaker tag, and the user wants to generate a question that the speaker might ask. But without knowing the topic, it's speculative. Since the input doesn't include the actual question, perhaps the correct approach is to output the input as-is because it's not a question and lacks context. But the user's example might have different expectations. Wait, the input is "Jack Fleven (Jefferies)" and the desired output is a question. Let me think again. If this is part of an earnings call, maybe the question is "What is your outlook for the company's growth in the next quarter, Jack Fleven (Jefferies)?" But again, that's making assumptions. Alternatively, perhaps the input is a name and firm, and the task is to create a question that the analyst might ask, like "Can you discuss the company's Q2 results?" But without knowing the specific context, the question is too generic. Given the strict rules, if the input isn't a question and lacks enough info, output as-is. But the user's example might expect a question. Maybe the correct answer here is to output "What are your key concerns or questions for the management team, Jack Fleven (Jefferies)?" but that's still speculative. Alternatively, maybe the input is part of a list of participants in an earnings call, and the user wants to generate a question based on that. However, without the actual content of the question, it's impossible to form a specific one. Given the rules, since the input isn't a question and lacks enough information to form a clear earnings-call question, the output should be the input as-is. But wait, the user's instruction says if a rewrite is possible, end with a question mark. If it's not possible, output as-is. But is it possible to form a question here? Maybe not. So the answer would be "Jack Fleven (Jefferies)" without a question mark. However, the user's example might expect a question. Let me check the rules again: "If the input is NOT a question, is too vague, or lacks enough information to form a clear earnings-call question, output the input EXACTLY as-is, with no modification." In this case, the input is not a question and lacks enough info. So the correct output is "Jack Fleven (Jefferies)" without any changes - Jack Fleven (Jefferies)

2026Q2: G&A as a percentage of revenue improved over 2% year-over-year and is expected to exit the year at ~6%. - Brandon Sim(CEO)

How much of the G&A improvements come from Prospect synergies versus core efficiency and AI initiatives? - Christian Borgmeyer (TD Cowen)

2025Q4: The company's G&A efficiency (down ~110 bps on an adjusted basis year-over-year) is driven by the AI infrastructure. - Brandon Sim(CEO)